Endo International PLC (NASDAQ: ENDP) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company reported preliminary results for the quarter ending September 30th that beat expectations. Of course, this led to excitement among investors, who are sending the stock toward the top. This prompted an alert from our partners at Trade Ideas. Currently (9:50), ENDP is trading at $6.41 per share after a gain of $0.53 per share (9.01%) thus far today.
ENDP Gains On Preliminary Financial Results
As mentioned above, Endo International reported preliminary financial results for the quarter ending September 30th early this morning. Those results proved to be overwhelmingly positive. Here’s what we saw from the press release:
Revenue – ENDP didn’t disappoint with regard to revenue. In fact, the results came right in line with expectations. During the quarter, analysts expected that the company would report revenue in the amount of $784.8 million. In the preliminary results, the company said it earned $785 million.
Loss – The company also said that it expects to report a loss of approximately $100 million.
EBITDA – On the EBITDA side, the company announced that the figure came in at approximately $370 million or $0.45 per share.
EPS – Finally, in terms of EPS, ENDP did incredibly well. During the quarter, the company announced earnings per share in the amount of $0.85.
In terms of guidance, Endo International confirmed the positive guidance investors have been expecting to see. For the twelve months ending on December 31, 2017, the company expects that revenue will come in between $3.38 billion and $3.53 billion. Also, it is expected that EBITDA and EPS will be at the upper end of the 2017 guidance ranges. This range is between $1.48 and $1.56 billion and between $3.35 and $3.65 per share respectively.
Furthermore, ENDP talked more about the protection of VASOSTRICT®. In the statement, ENDP said that it intends to aggressively protect this particular product franchise and intellectual property, working to prevent the unapproved, non-sterile-to-sterile bulk compounding of vasopressin through a previously announced lawsuit filed by its subsidiaries against the FDA on October 26, 2017. Currently, VASOSTRICT remains as the only FDA-approved vasopressin injection product indicated to increase blood pressure in patients with vasodilatory shock who remain hypotensive despite fluids and cateholamines.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ENDP. In particular, we’re interested in following the ongoing growth of the company. We’re also interested in following the company’s efforts to protect ASOSTRICT from competing products through the lawsuit that was filed earlier this month. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!